Evidence map›Paper›PMID 27562847›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2016

Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.

Jie Wen, Prasanth S Ariyannur, Rachel Ribeiro, Mikiei Tanaka, John R Moffett, Batool F Kirmani, Aryan M A Namboodiri, Yumin Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Melatonin and Microglia.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jie WenDepartment of Anatomy, Physiology and Genetics, Neuroscience Program, Bldg. C, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.
Prasanth S AriyannurMolecular Diagnostics Div., Department of Medical Oncology, Amrita Institute of Medical Sciences, Amrita University, Kochi, India.
Rachel RibeiroDepartment of Anatomy, Physiology and Genetics, Neuroscience Program, Bldg. C, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.
Mikiei TanakaDepartment of Anatomy, Physiology and Genetics, Neuroscience Program, Bldg. C, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.
John R MoffettDepartment of Anatomy, Physiology and Genetics, Neuroscience Program, Bldg. C, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.
Batool F KirmaniEpilepsy Center, Department of Neurology, Scott and White Hospital, Texas A&M University, Temple, TX, USA.
Aryan M A NamboodiriDepartment of Anatomy, Physiology and Genetics, Neuroscience Program, Bldg. C, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA. anamboodiri@usuhs.edu.
Yumin ZhangDepartment of Anatomy, Physiology and Genetics, Neuroscience Program, Bldg. C, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA. yumin.zhang@usuhs.edu.
Uniformed Services University of the Health Sciences · USAmrita Institute of Medical Sciences and Research Centre · INScott & White Memorial Hospital · US

Funding

Acetate Supplementation as a therapeutic strategy for Canavan diseaseR21NS084206 · NINDS · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI NAMBOODIRI, ARYAN MANGALAM · 2014 to 2015
$418k
NINDS NIH HHS R21 NS084206
6 · The paper itself

Abstract

Melatonin and N-acetylserotonin (NAS) are tryptophan metabolites that have potent anti-oxidant, anti-inflammatory and neuroprotective properties in several animal models of neurological injury and disease including multiple sclerosis (MS). The therapeutic effect of NAS has not been reported previously in experimental autoimmune encephalomyelitis (EAE), a commonly used animal model of MS. Using a MOG-peptide induced EAE mouse model we examined the effects of melatonin and NAS on clinical score, inflammatory markers, free radical generation, and sparing of axons, oligodendrocytes and myelin. We found that NAS and melatonin reduced clinical scores when administered prior to or after symptom onset. This effect was more pronounced when melatonin and NAS were administrated prior to symptom onset whereby the appearance of motor symptoms was significantly delayed. Activated microglia and CD4

Indexed as

Disease Models, AnimalAnimalsCells, CulturedEncephalomyelitis, Autoimmune, ExperimentalFemaleMelatoninMiceMice, Inbred C57BLMultiple SclerosisSerotoninTreatment OutcomeMelatoninN-acetylserotoninSerotoninDemyelinationExperimental autoimmune encephalomyelitisIndoleamine 2,3 dioxygenaseInflammationMicrogliaNeuroprotectionReactive oxygen species

Identifiers

PMID27562847
OpenAlexW2509677476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.